Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Atrium Therapeutics Inc (RNA)

Atrium Therapeutics Inc (RNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Jul 20, 4:58PM CDT

SAN DIEGO , July 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on July 20, 2026 under the Company's 2026 Employment...

RNA : 11.35 (-0.96%)
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome PR Newswire - Tue Jul 14, 5:30AM CDT

-- ATR 1072 is the company's first precision cardiology program to enter the clinic --

RNA : 11.35 (-0.96%)
Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Tue Jun 23, 3:05PM CDT

SAN DIEGO , June 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on June 20, 2026 under the Company's 2026 Employment...

RNA : 11.35 (-0.96%)
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PR Newswire - Thu Apr 23, 7:00AM CDT

SAN DIEGO , April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced...

RNA : 11.35 (-0.96%)
BMY : 65.31 (+0.69%)
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire - Mon Apr 20, 9:46PM CDT

SAN DIEGO , April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment...

RNA : 11.35 (-0.96%)
Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies PR Newswire - Fri Feb 27, 8:19AM CST

Spinoff from Novartis AG's acquisition of Avidity Biosciences advances precision cardiology programs using targeted RNA delivery platform

RNA : 11.35 (-0.96%)
Avidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire - Thu Feb 26, 3:02PM CST

SAN DIEGO , Feb. 26, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 11.35 (-0.96%)
Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of Stockholders PR Newswire - Mon Feb 23, 7:00AM CST

SAN DIEGO , Feb. 23, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (NASDAQ: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

RNA : 11.35 (-0.96%)
The New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 PR Newswire - Wed Feb 18, 4:00PM CST

Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing

RNA : 11.35 (-0.96%)
Avidity Biosciences Announces Expected Record Date for Spin-Off PR Newswire - Mon Feb 2, 8:44PM CST

SAN DIEGO , Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide...

RNA : 11.35 (-0.96%)

Barchart Exclusives

Wall Street Is Rewarding AI Results, Not Just AI Spending Barchart - Sun Aug 2, 4:19PM CDT
The market is buying CEO Andy Jassy's spending plan for Amazon. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.